Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy

被引:0
作者
Yanai, Yoshinori [1 ]
Mikami, Shuji [2 ]
Yasumizu, Yota [1 ]
Takeda, Toshikazu [1 ]
Matsumoto, Kazuhiro [1 ]
Kitano, Shigehisa [3 ]
Oya, Mototsugu [1 ]
Kosaka, Takeo [1 ]
机构
[1] Keio Univ, Dept Urol, Sch Med, 35 Shinanomachi,Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Diagnost Pathol, Tokyo, Japan
[3] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Dept Adv Med Dev, Div Clin Chemotherapy,Canc Inst Hosp, Tokyo, Japan
关键词
biochemical recurrence; phosphatase and tensin homolog; prostate cancer; prostatectomy; tumor suppressor genes; PTEN; DOCETAXEL;
D O I
10.1111/iju.15592
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study aimed to investigate the potential for using the phosphatase and tensin homolog (PTEN) gene as a prognostic marker in post-prostatectomy patients with castration-sensitive prostate cancer (PCa). Methods A total of 180 patients with castration-sensitive PCa who underwent radical prostatectomy at our institution were included in this study. PTEN expression was evaluated using immunohistochemistry, and patients were classified into two groups based on the staining intensity: PTEN-Normal and PTEN-Loss. The association between PTEN expression and biochemical recurrence was analyzed using the Cox proportional hazards model. Results Patients in the PTEN-Loss group had a higher risk of biochemical recurrence (hazard ratio, 4.642; 95% confidence interval, 2.137-10.083; p < 0.001) and a lower recurrence-free rate compared to the PTEN-Normal group (35% vs. 75%). In addition to clinicopathological factors, such as the serum prostate-specific antigen level, Gleason score, and T stage, evaluation of PTEN expression improved the prediction of biochemical recurrence after prostatectomy (area under the curve, 0.577 vs. 0.688). Conclusions Low PTEN expression is a significant predictor of biochemical recurrence in patients with castration-sensitive PCa who have already undergone prostatectomy.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 30 条
[1]   A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer [J].
Ahearn, Thomas U. ;
Pettersson, Andreas ;
Ebot, Ericka M. ;
Gerke, Travis ;
Graff, Rebecca E. ;
Morais, Carlos L. ;
Hicks, Jessica L. ;
Wilson, Kathryn M. ;
Rider, Jennifer R. ;
Sesso, Howard D. ;
Fiorentino, Michelangelo ;
Flavin, Richard ;
Finn, Stephen ;
Giovannucci, Edward L. ;
Loda, Massimo ;
Stampfer, Meir J. ;
De Marzo, Angelo M. ;
Mucci, Lorelei A. ;
Lotan, Tamara L. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02)
[2]   An Immunohistochemical Signature Comprising PTEN, MYC, and Ki67 Predicts Progression in Prostate Cancer Patients Receiving Adjuvant Docetaxel After Prostatectomy [J].
Antonarakis, Emmanuel S. ;
Keizman, Daniel ;
Zhang, Zhe ;
Gurel, Bora ;
Lotan, Tamara L. ;
Hicks, Jessica L. ;
Fedor, Helen L. ;
Carducci, Michael A. ;
De Marzo, Angelo M. ;
Eisenberger, Mario A. .
CANCER, 2012, 118 (24) :6063-6071
[3]   Chromosomal imbalances, and immunohistochemical loss of heterozygosity, expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate [J].
Bettendorf, Olaf ;
Schmidt, Hartmut ;
Staebler, Annette ;
Grobholz, Rainer ;
Heinecke, Achim ;
Boecker, Werner ;
Hertle, Lothar ;
Semjonow, Axel .
GENES CHROMOSOMES & CANCER, 2008, 47 (07) :565-572
[4]   Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].
de Bono, J. ;
Mateo, J. ;
Fizazi, K. ;
Saad, F. ;
Shore, N. ;
Sandhu, S. ;
Chi, K. N. ;
Sartor, O. ;
Agarwal, N. ;
Olmos, D. ;
Thiery-Vuillemin, A. ;
Twardowski, P. ;
Mehra, N. ;
Goessl, C. ;
Kang, J. ;
Burgents, J. ;
Wu, W. ;
Kohlmann, A. ;
Adelman, C. A. ;
Hussain, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102
[5]   Defining the role of mTOR in cancer [J].
Guertin, David A. ;
Sabatini, David M. .
CANCER CELL, 2007, 12 (01) :9-22
[6]   The evolutionary history of lethal metastatic prostate cancer [J].
Gundem, Gunes ;
Van Loo, Peter ;
Kremeyer, Barbara ;
Alexandrov, Ludmil B. ;
Tubio, Jose M. C. ;
Papaemmanuil, Elli ;
Brewer, Daniel S. ;
Kallio, Heini M. L. ;
Hoegnas, Gunilla ;
Annala, Matti ;
Kivinummi, Kati ;
Goody, Victoria ;
Latimer, Calli ;
O'Meara, Sarah ;
Dawson, Kevin J. ;
Isaacs, William ;
Emmert-Buck, Michael R. ;
Nykter, Matti ;
Foster, Christopher ;
Kote-Jarai, Zsofia ;
Easton, Douglas ;
Whitaker, Hayley C. ;
Neal, David E. ;
Cooper, Colin S. ;
Eeles, Rosalind A. ;
Visakorpi, Tapio ;
Campbell, Peter J. ;
McDermott, Ultan ;
Wedge, David C. ;
Bova, G. Steven .
NATURE, 2015, 520 (7547) :353-+
[7]   Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer [J].
Hongo, Hiroshi ;
Kosaka, Takeo ;
Oya, Mototsugu .
CANCER SCIENCE, 2018, 109 (09) :2937-2945
[8]   Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy [J].
Humid, Anis A. ;
Gray, Kathryn P. ;
Huang, Ying ;
Bowden, Michaela ;
Pomerantz, Mark ;
Loda, Massimo ;
Sweeney, Christopher J. .
EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (05) :475-482
[9]   Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer [J].
Humid, Anis A. ;
Gray, Kathryn P. ;
Shaw, Grace ;
MacConaill, Laura E. ;
Evan, Carolyn ;
Bernard, Brandon ;
Loda, Massimo ;
Corcoran, Niall M. ;
Van Allen, Eliezer M. ;
Choudhury, Atish D. ;
Sweeney, Christopher J. .
EUROPEAN UROLOGY, 2019, 76 (01) :89-97
[10]   Prostate cancer in Asian men [J].
Ito, Kazuto .
NATURE REVIEWS UROLOGY, 2014, 11 (04) :197-212